What we’re watching

A point-of-sale clinical review identified two medications with overlapping mechanisms of action, helping support a more clinically appropriate diabetes treatment plan.

Refill activity is monitored past the first fill, so gaps in therapy don't go unnoticed.

PharmPix identified a medication combination associated with avoidable renal risk and gave the prescriber clinically appropriate alternatives.

A point-of-sale clinical review identified a montelukast dose that exceeded FDA pediatric recommendations for the patient’s age.

A biosimilar is only as good as the transition supporting it. Confirm the patient is appropriate for conversion, communicate the switch directly rather than relying on the pharmacy to explain it, and build in a follow-up touchpoint in the weeks after the switch to confirm continuity before assuming…

For self-funded groups or groups that have carved out their pharmacy benefit, biosimilar adoption has become a practical test of PBM performance. The opportunity is real: biologics account for just 5% of prescriptions but 51% of drug spending, according to the FDA, and biosimilars generated $20.2…